Description

Onilcamotide (RV001) is a C-terminal peptide of RhoC protein. Onilcamotide is a cancer vaccine and has potential immunomodulating and antineoplastic activities[1].—COVID-19-immunoregulation–C96H177N39O24S—-[1]Schuhmacher J, et al. Vaccination against RhoC induces long-lasting immune responses in patients with prostate cancer: results from a phase I/II clinical trial. J Immunother Cancer. 2020;8(2):e001157.–1164096-85-8–2293.75—-CC(C)C[C@@H](C(O)=O)NC([C@H]([C@@H](C)CC)NC([C@H]1N(CCC1)C([C@H](CS)NC(CNC([C@H](CCCNC(N)=N)NC([C@H](CCCNC(N)=N)NC([C@H](CCCNC(N)=N)NC([C@H](CCCCN)NC([C@H](CC(N)=O)NC([C@H](CCCCN)NC([C@H](CCCNC(N)=N)NC([C@H](C(C)C)NC([C@H](CCC(N)=O)NC([C@H](CC(C)C)NC(CNC([C@H](C)NC([C@H](CCCNC(N)=N)NC([C@H]([C@H](O)C)NC([C@@H](N)C)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O–Cancer; Inflammation/Immunology–10 mM in DMSO–Others—-Others–Peptides